Our study reveals that serum levels of interleukin (IL6), IL8, and surfactant protein-D (SP-D) can be used as early markers to stratify the severity of COVID-19, even on the day of hospitalization and before hypoxia sets in. This evidence concerns the gene SFTPD and COVID-19.